Cisplatin treatment can be associated with significant short-lived cardiotoxicity, specifically bradycardia.
Cisplatin may cause transient bradycardia warranting monitoring; single case leaves open incidence, risk factors, and causality.
Cisplatin is a very common chemotherapeutic agent used in the treatment of gynecologic malignancies, including cervical, ovarian, and endometrial cancers. Bradycardia is a rare, though potentially severe, side effect of this medication. Here we present the case of a young woman with ovarian cancer who demonstrated significant short-lived cardiotoxicity associated with cisplatin treatment.
No takes yet. Share an insight, caveat, or question.
Schlumbrecht et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: